In its early years, mass spectrometry (MS)-based proteomics focused on the cataloging of
proteins found in different species or different tissues. By 2005, proteomics was being used …

Accurate cancer biomarkers are needed for early detection, disease classification, prediction
of therapeutic response and monitoring treatment. While there appears to be no shortage of …

Accurate and rapid protein quantitation is essential for screening biomarkers for disease
stratification and monitoring, and to validate the hundreds of putative markers in human …

The use of protein biomarkers as surrogates for clinical endpoints requires extensive
multilevel validation including development of robust and sensitive assays for precise …

Objective: Plasma protein biomarkers could be an efficient alternative for population-based
screening for early detection of colorectal cancer (CRC). The objective of this study was to …

Although genomics has delivered major advances in cancer prognostics, treatment and
diagnostics, it still only provides a static image of the situation. To study more dynamic …

Spurred on by the growing demand for panels of validated disease biomarkers, increasing
efforts have focused on advancing qualitative and quantitative tools for more highly …

Blood-based protein biomarker signatures might be an alternative or supplement to existing
methods for early detection of colorectal cancer (CRC) for population-based screening. The …

There exists a growing demand in the proteomics community to standardize experimental
methods and liquid chromatography–mass spectrometry (LC/MS) platforms in order to …

Blood proteome analysis for biomarker discovery represents one of the most challenging
tasks to be achieved through clinical proteomics due to the sample complexity, such as the …